MX2019000205A - Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. - Google Patents
Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.Info
- Publication number
- MX2019000205A MX2019000205A MX2019000205A MX2019000205A MX2019000205A MX 2019000205 A MX2019000205 A MX 2019000205A MX 2019000205 A MX2019000205 A MX 2019000205A MX 2019000205 A MX2019000205 A MX 2019000205A MX 2019000205 A MX2019000205 A MX 2019000205A
- Authority
- MX
- Mexico
- Prior art keywords
- exogenous rna
- compositions
- methods related
- cell systems
- therapeutic cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 3
- 108091023045 Untranslated Region Proteins 0.000 abstract 1
- 238000007385 chemical modification Methods 0.000 abstract 1
- 210000000267 erythroid cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/18—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/50—Biochemical production, i.e. in a transformed host cell
- C12N2330/51—Specially adapted vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
- C12N2501/734—Proteases (EC 3.4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
- G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Developmental Biology & Embryology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La invención incluye composiciones y métodos relacionados con células eritroides que comprenden ARN exógeno que codifica una proteína. El ARN exógeno puede comprender una región no traducida heteróloga que comprende un elemento regulador. Como alternativa o en combinación, el ARN exógeno puede comprender modificaciones químicas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662359416P | 2016-07-07 | 2016-07-07 | |
PCT/US2017/041155 WO2018009838A1 (en) | 2016-07-07 | 2017-07-07 | Compositions and methods related to therapeutic cell systems expressing exogenous rna |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019000205A true MX2019000205A (es) | 2019-09-23 |
Family
ID=59564224
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019000205A MX2019000205A (es) | 2016-07-07 | 2017-07-07 | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20190161730A1 (es) |
EP (1) | EP3481943A1 (es) |
JP (2) | JP2019520829A (es) |
KR (1) | KR20190026819A (es) |
CN (1) | CN109526226A (es) |
AU (1) | AU2017293931A1 (es) |
BR (1) | BR112019000195A2 (es) |
CA (1) | CA3029906A1 (es) |
MX (1) | MX2019000205A (es) |
WO (1) | WO2018009838A1 (es) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015073587A2 (en) | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
EP3125927B1 (en) | 2014-04-01 | 2021-01-27 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
LT3402491T (lt) | 2016-01-11 | 2022-02-25 | Rubius Therapeutics, Inc. | Kompozicijos ir būdai, susiję su daugiamodalinėmis terapinėmis ląstelių sistemomis, skirti vėžio indikacijoms |
JP2020507329A (ja) | 2017-02-17 | 2020-03-12 | ルビウス セラピューティクス, インコーポレイテッド | 機能化赤血球系細胞 |
EP3703751A2 (en) | 2017-11-03 | 2020-09-09 | Rubius Therapeutics, Inc. | Compositions and methods related to therapeutic cell systems for tumor growth inhibition |
CN111712254A (zh) | 2017-12-23 | 2020-09-25 | 鲁比厄斯治疗法股份有限公司 | 人工抗原呈递细胞和使用方法 |
US20190201548A1 (en) | 2017-12-29 | 2019-07-04 | Rubius Therapeutics, Inc. | Gene editing and targeted transcriptional modulation for engineering erythroid cells |
US20190330591A1 (en) | 2018-01-10 | 2019-10-31 | Rubius Therapeutics, Inc. | Amplifiable rnas for therapeutic cell systems |
CN108192976B (zh) * | 2018-03-02 | 2021-06-04 | 中南大学湘雅医院 | 长链非编码rna linc00336作为生物标志物在制备肺鳞癌预后检测制剂中的应用 |
CN108192973B (zh) * | 2018-03-02 | 2021-06-04 | 中南大学湘雅医院 | 长链非编码rna linc00559作为生物标志物在制备肺腺癌预后检测制剂中的应用 |
CN108192975B (zh) * | 2018-03-02 | 2021-06-04 | 中南大学湘雅医院 | 长链非编码rna linc00559作为生物标志物在制备肺鳞癌预后检测制剂中的应用 |
AU2019232012A1 (en) | 2018-03-08 | 2020-09-24 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating cancer and infectious diseases |
US20190309271A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating homocystinuria |
US20190309269A1 (en) | 2018-03-20 | 2019-10-10 | Rubius Therapeutics, Inc. | Therapeutic cell systems and methods for treating hyperuricemia and gout |
CN108588220A (zh) * | 2018-04-26 | 2018-09-28 | 汕头大学医学院附属肿瘤医院 | 食管鳞癌长链非编码rna linc01419分子标志物及其应用 |
CN108559779B (zh) * | 2018-06-13 | 2020-01-14 | 中国医学科学院北京协和医院 | 长链非编码rna作为胃癌的诊治标志物 |
CN110607299B (zh) * | 2018-06-14 | 2022-04-05 | 中国科学技术大学 | 887s rna及其在抑制肿瘤中的应用 |
CN110607298B (zh) * | 2018-06-14 | 2022-04-05 | 中国科学技术大学 | 887l rna抑制物及其在抑制肿瘤中的应用 |
CN109207581A (zh) * | 2018-09-25 | 2019-01-15 | 深圳市人民医院 | 一种自身免疫性疾病诊断试剂盒和应用 |
AU2019394875A1 (en) | 2018-12-03 | 2021-06-17 | Rubius Therapeutics, Inc. | Artificial antigen presenting cells including HLA-E and HLA-G molecules and methods of use |
US11166996B2 (en) | 2018-12-12 | 2021-11-09 | Flagship Pioneering Innovations V, Inc. | Anellovirus compositions and methods of use |
MX2021008592A (es) | 2019-01-18 | 2021-12-15 | Flagship Pioneering Inc | Composiciones de trem y usos de las mismas. |
CA3130750A1 (en) | 2019-02-20 | 2020-08-27 | Rubius Therapeutics, Inc. | Engineered erythroid cells including loadable antigen-presenting polypeptides and methods of use |
CN109762821B (zh) * | 2019-02-28 | 2021-10-01 | 中山大学孙逸仙纪念医院 | 抑制afap1-as1表达的干扰rna及在增加乳腺癌放疗敏感性中的应用 |
KR20210135265A (ko) | 2019-03-04 | 2021-11-12 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 원형 폴리리보뉴클레오티드 및 그의 약제학적 조성물 |
US20220152082A1 (en) * | 2019-03-07 | 2022-05-19 | Anpac Bio-Medical Science Co., Ltd. | Methods for Cancer Diagnosis, Prognosis or Treatment |
US20230072532A1 (en) | 2019-03-25 | 2023-03-09 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising modified circular polyribonucleotides and uses thereof |
CN110029166B (zh) * | 2019-04-23 | 2020-09-22 | 浙江大学 | 长链非编码rna linc00205在制备诊断卵巢癌试剂或治疗卵巢癌药物中的应用 |
EP3976782A1 (en) | 2019-05-31 | 2022-04-06 | Flagship Pioneering, Inc. | Uses of trem compositions to modulate trna pools |
CN114007655A (zh) | 2019-06-14 | 2022-02-01 | 旗舰创业创新第六有限责任公司 | 用于细胞疗法的环状rna |
US20220305128A1 (en) | 2019-06-19 | 2022-09-29 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof |
EP3990005A1 (en) | 2019-06-26 | 2022-05-04 | Travere Therapeutics Switzerland GmbH | Pegylated cystathionine beta synthase for enzyme therapy for treatment of homocystinuria |
GB201913592D0 (en) * | 2019-09-20 | 2019-11-06 | Univ Bristol | Product for therapy and methods |
KR20220128611A (ko) | 2019-11-04 | 2022-09-21 | 플래그쉽 파이어니어링, 인크. | 맥락적 희귀 코돈용 trem 조성물 및 관련 용도 |
EP4055169A1 (en) | 2019-11-04 | 2022-09-14 | Flagship Pioneering, Inc. | Methods of modifying a nucleic acid sequence |
CN110628915A (zh) * | 2019-11-06 | 2019-12-31 | 成都医学院第一附属医院 | lncRNA LSAMP-AS1作为胃癌诊断标志物的应用 |
CN112852741A (zh) * | 2019-11-28 | 2021-05-28 | 华东师范大学 | 一种嵌合抗原受体t细胞及其制备方法和细胞药物 |
TW202142239A (zh) | 2020-01-29 | 2021-11-16 | 美商旗艦先鋒創新有限責任公司 | 包含環狀多核糖核苷酸之組合物之遞送 |
EP4096682A1 (en) | 2020-01-29 | 2022-12-07 | Flagship Pioneering Innovations VI, LLC | Compositions for translation and methods of use thereof |
WO2021155177A1 (en) | 2020-01-29 | 2021-08-05 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising linear polyribonucleotides for protein modulation and uses thereof |
JP2023513263A (ja) | 2020-02-10 | 2023-03-30 | ルビウス セラピューティクス, インコーポレイテッド | Hla-gポリペプチドを含む操作された赤血球系細胞およびその使用方法 |
CN111214482B (zh) * | 2020-02-21 | 2022-11-11 | 东莞市第八人民医院(东莞市儿童医院) | 一种靶向linc00467基因的siRNA在白血病耐药性中的应用 |
CN111154882B (zh) * | 2020-03-09 | 2020-12-08 | 深圳市康百得生物科技有限公司 | 长链非编码rna linc01107在制备白血病诊断试剂盒上的应用 |
CN111394351B (zh) * | 2020-03-18 | 2023-11-07 | 济南爱新卓尔医学检验有限公司 | 一种抑制DICER1-AS1表达的siRNA及其应用 |
CN111893120B (zh) * | 2020-03-20 | 2021-10-19 | 浙江生研生物科技有限公司 | 长链非编码rna linc01141在制备治疗肝癌药物组合物中的应用 |
CN111534515A (zh) * | 2020-04-15 | 2020-08-14 | 湖南省科域生物医药科技有限公司 | Mir143hg作为抑制前列腺癌细胞增殖、侵袭与转移的用途 |
WO2021236952A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering, Inc. | Compositions and methods for producing human polyclonal antibodies |
TW202208629A (zh) | 2020-05-20 | 2022-03-01 | 美商旗艦先鋒創新有限責任公司 | 免疫原性組成物及其用途 |
WO2021236980A1 (en) | 2020-05-20 | 2021-11-25 | Flagship Pioneering Innovations Vi, Llc | Coronavirus antigen compositions and their uses |
WO2021243301A2 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
US20230203510A1 (en) | 2020-05-29 | 2023-06-29 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods relating thereto |
EP4167984A1 (en) | 2020-06-23 | 2023-04-26 | Flagship Pioneering, Inc. | Anti-viral compounds and methods of using same |
CN111647660B (zh) * | 2020-07-09 | 2021-03-16 | 河南省人民医院 | Linc01559在胃癌诊断及治疗中的应用 |
AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
WO2022140702A1 (en) | 2020-12-23 | 2022-06-30 | Flagship Pioneering, Inc. | Compositions of modified trems and uses thereof |
AU2022246895A1 (en) | 2021-03-31 | 2023-10-19 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
CN113278695B (zh) * | 2021-04-12 | 2022-09-02 | 山东大学第二医院 | Linc00969在肝癌诊断生物标志物及治疗靶点中的应用 |
CN113322318B (zh) * | 2021-05-13 | 2022-03-04 | 武汉大学中南医院 | Linc00485作为分子标志物在制备用于诊断和/或预后肝细胞癌的产品中的应用 |
WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
CN113430273B (zh) * | 2021-08-17 | 2022-05-27 | 广州齐凯生物科技有限公司 | 长链非编码rna linc01565在急性髓系白血病预后中的应用 |
CN113652483B (zh) * | 2021-08-19 | 2024-04-26 | 复旦大学附属中山医院 | 长链非编码RNA及特异性干扰长链非编码RNA表达的siRNA的应用 |
CN118234867A (zh) | 2021-09-17 | 2024-06-21 | 旗舰创业创新六公司 | 用于产生环状多核糖核苷酸的组合物和方法 |
CN118382705A (zh) | 2021-10-18 | 2024-07-23 | 旗舰创业创新六公司 | 用于纯化多核糖核苷酸的组合物和方法 |
CN113862366A (zh) * | 2021-10-26 | 2021-12-31 | 山东师范大学 | 一种肝癌诊断的生物标志物及其诊断试剂盒 |
WO2023075122A1 (ko) * | 2021-10-26 | 2023-05-04 | 사회복지법인 삼성생명공익재단 | 대장암의 치료 및 전이 억제용 약학적 조성물 및 이의 용도 |
AU2022397300A1 (en) | 2021-11-24 | 2024-06-27 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and their uses |
AU2022398478A1 (en) | 2021-11-24 | 2024-06-13 | Flagship Pioneering Innovations Vi, Llc | Coronavirus immunogen compositions and their uses |
AU2022397292A1 (en) | 2021-11-24 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Varicella-zoster virus immunogen compositions and their uses |
TW202340461A (zh) | 2021-12-22 | 2023-10-16 | 美商旗艦先鋒創新有限責任公司 | 用於純化多核糖核苷酸之組成物和方法 |
TW202342064A (zh) | 2021-12-23 | 2023-11-01 | 美商旗艦先鋒創新有限責任公司 | 編碼抗融合多肽之環狀多核糖核苷酸 |
CN115247176B (zh) * | 2022-01-17 | 2023-06-20 | 郑州大学第一附属医院 | 一种长链非编码rna及其应用 |
WO2023220083A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
WO2023230578A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating circulating factors |
WO2023230549A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of tumor suppressors and oncogenes |
WO2023230570A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating genetic drivers |
WO2023230566A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulating cytokines |
WO2023230573A2 (en) | 2022-05-25 | 2023-11-30 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for modulation of immune responses |
WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
CN115927611A (zh) * | 2022-07-26 | 2023-04-07 | 南通大学 | 一种乳腺癌的生物标志物及其应用 |
WO2024035613A1 (en) * | 2022-08-09 | 2024-02-15 | Eligab Tx Llc | Optimized gapmers antisense oligonucleotides for increasing foxg1 expression |
CN116064767B (zh) * | 2022-08-23 | 2024-06-04 | 南京医科大学 | 一种与骨关节炎相关的LncRNA标志物及其应用 |
WO2024072890A1 (en) * | 2022-09-28 | 2024-04-04 | Mayo Foundation For Medical Education And Research | Targeting cancer with fto-it1 long noncoding rna antisense oligonucleotides |
US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
WO2024097664A1 (en) | 2022-10-31 | 2024-05-10 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
WO2024102799A1 (en) | 2022-11-08 | 2024-05-16 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for producing circular polyribonucleotides |
WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
WO2024151685A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
US20240238473A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
US20240293582A1 (en) | 2023-02-17 | 2024-09-05 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
US20240285805A1 (en) | 2023-02-17 | 2024-08-29 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316254B1 (en) * | 1994-02-14 | 2001-11-13 | University Of Washington | Methods for stimulating erythropoiesis using hematopoietic proteins |
US20050287539A1 (en) | 2004-06-29 | 2005-12-29 | Emmanuel Labourier | Methods and compositions for preparing capped RNA |
EP4332227A1 (en) | 2005-08-23 | 2024-03-06 | The Trustees of the University of Pennsylvania | Rna containing modified nucleosides and methods of use thereof |
CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
US20100323393A1 (en) * | 2009-06-23 | 2010-12-23 | Xiuli An | Ordered Assembly of Membrane Proteins During Differentiation of Erythroblasts |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
WO2012045082A2 (en) | 2010-10-01 | 2012-04-05 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
ES2618127T3 (es) | 2010-10-27 | 2017-06-20 | President And Fellows Of Harvard College | Composiciones de dúplex de cebador de extremos cohesivos y métodos de uso |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
BR112013029490A2 (pt) | 2011-05-17 | 2019-09-24 | Moderna Therapeutics Inc | ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos |
US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
EP2755693A4 (en) | 2011-09-12 | 2015-05-20 | Moderna Therapeutics Inc | MODIFIED NUCLEIC ACIDS AND METHODS OF USE |
WO2013039857A1 (en) | 2011-09-12 | 2013-03-21 | modeRNA Therapeutics | Engineered nucleic acids and methods of use thereof |
EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
US20140378538A1 (en) | 2011-12-14 | 2014-12-25 | Moderma Therapeutics, Inc. | Methods of responding to a biothreat |
DK2791160T3 (da) | 2011-12-16 | 2022-05-30 | Modernatx Inc | Modificerede mrna-sammensætninger |
WO2013096709A2 (en) | 2011-12-21 | 2013-06-27 | modeRNA Therapeutics | Methods of increasing the viability or longevity of an organ or organ explant |
EP2797634A4 (en) | 2011-12-29 | 2015-08-05 | Moderna Therapeutics Inc | MODIFIED mRNA ENCODING POLYPEPTIDES PENETRATING IN CELLS |
WO2013106496A1 (en) | 2012-01-10 | 2013-07-18 | modeRNA Therapeutics | Methods and compositions for targeting agents into and across the blood-brain barrier |
DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
CA2868391A1 (en) | 2012-04-02 | 2013-10-10 | Stephane Bancel | Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same |
US9512456B2 (en) | 2012-08-14 | 2016-12-06 | Modernatx, Inc. | Enzymes and polymerases for the synthesis of RNA |
WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
HRP20220607T1 (hr) | 2012-11-26 | 2022-06-24 | Modernatx, Inc. | Terminalno modificirana rna |
US20150315541A1 (en) | 2012-12-13 | 2015-11-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
JP2016506740A (ja) * | 2013-02-08 | 2016-03-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 無細胞翻訳系 |
US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
WO2014158795A1 (en) | 2013-03-12 | 2014-10-02 | Moderna Therapeutics, Inc. | Diagnosis and treatment of fibrosis |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
US20160032273A1 (en) | 2013-03-15 | 2016-02-04 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
US11377470B2 (en) | 2013-03-15 | 2022-07-05 | Modernatx, Inc. | Ribonucleic acid purification |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
US20160017313A1 (en) | 2013-03-15 | 2016-01-21 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014186508A1 (en) * | 2013-05-15 | 2014-11-20 | University Of Rechester | Human extensively self-renewing erythroblasts (esre) |
PL3019619T3 (pl) | 2013-07-11 | 2022-01-10 | Modernatx, Inc. | Kompozycje zawierające syntetyczne polinkleotydy kodujące białka powiązane z crispr i syntetyczne sgrna oraz sposoby ich stosowania |
EP3677567A1 (en) | 2013-07-23 | 2020-07-08 | Arbutus Biopharma Corporation | Compositions and methods for delivering messenger rna |
US20160194368A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Circular polynucleotides |
JP2016530294A (ja) | 2013-09-03 | 2016-09-29 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | キメラポリヌクレオチド |
US9925277B2 (en) | 2013-09-13 | 2018-03-27 | Modernatx, Inc. | Polynucleotide compositions containing amino acids |
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
WO2015051173A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc | Polynucleotide molecules and uses thereof |
EP3052521A1 (en) | 2013-10-03 | 2016-08-10 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
WO2015058069A1 (en) | 2013-10-18 | 2015-04-23 | Moderna Therapeutics, Inc. | Compositions and methods for tolerizing cellular systems |
WO2015073587A2 (en) * | 2013-11-18 | 2015-05-21 | Rubius Therapeutics, Inc. | Synthetic membrane-receiver complexes |
WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
EP2918275B1 (en) | 2013-12-13 | 2016-05-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
EP3092250A4 (en) | 2014-01-08 | 2017-05-24 | Moderna Therapeutics, Inc. | Polynucleotides for the in vivo production of antibodies |
EP3125927B1 (en) | 2014-04-01 | 2021-01-27 | Rubius Therapeutics, Inc. | Methods and compositions for immunomodulation |
RU2746406C2 (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
US20170136132A1 (en) | 2014-06-19 | 2017-05-18 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
US20170175129A1 (en) | 2014-06-19 | 2017-06-22 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
EP3157573A4 (en) | 2014-06-19 | 2018-02-21 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
JP2017522028A (ja) | 2014-07-16 | 2017-08-10 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 環状ポリヌクレオチド |
CA2955250A1 (en) | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
JP2017523777A (ja) | 2014-07-17 | 2017-08-24 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | ポリヌクレオチドの末端修飾 |
US20170210788A1 (en) | 2014-07-23 | 2017-07-27 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
EP3177732A4 (en) | 2014-08-08 | 2018-04-25 | ModernaTX, Inc. | Compositions and methods for the treatment of ophthalmic diseases and conditions |
WO2016036902A1 (en) | 2014-09-03 | 2016-03-10 | Moderna Therapeutics, Inc. | Tolerogenic compositions and methods |
EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
WO2016077123A1 (en) | 2014-11-10 | 2016-05-19 | Moderna Therapeutics, Inc. | Multiparametric nucleic acid optimization |
WO2016183482A1 (en) | 2015-05-13 | 2016-11-17 | Rubius Therapeutics, Inc. | Membrane-receiver complex therapeutics |
-
2017
- 2017-07-07 JP JP2018569000A patent/JP2019520829A/ja not_active Withdrawn
- 2017-07-07 AU AU2017293931A patent/AU2017293931A1/en not_active Abandoned
- 2017-07-07 CN CN201780044400.4A patent/CN109526226A/zh active Pending
- 2017-07-07 WO PCT/US2017/041155 patent/WO2018009838A1/en unknown
- 2017-07-07 EP EP17749550.4A patent/EP3481943A1/en not_active Withdrawn
- 2017-07-07 CA CA3029906A patent/CA3029906A1/en active Pending
- 2017-07-07 BR BR112019000195-6A patent/BR112019000195A2/pt not_active Application Discontinuation
- 2017-07-07 MX MX2019000205A patent/MX2019000205A/es unknown
- 2017-07-07 KR KR1020197003248A patent/KR20190026819A/ko not_active Application Discontinuation
- 2017-07-07 US US16/315,967 patent/US20190161730A1/en not_active Abandoned
-
2021
- 2021-09-22 JP JP2021154086A patent/JP2021191304A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20190161730A1 (en) | 2019-05-30 |
JP2019520829A (ja) | 2019-07-25 |
CN109526226A (zh) | 2019-03-26 |
AU2017293931A1 (en) | 2019-01-17 |
KR20190026819A (ko) | 2019-03-13 |
EP3481943A1 (en) | 2019-05-15 |
JP2021191304A (ja) | 2021-12-16 |
BR112019000195A2 (pt) | 2019-04-24 |
WO2018009838A1 (en) | 2018-01-11 |
CA3029906A1 (en) | 2018-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2019000205A (es) | Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno. | |
PH12018502645A1 (en) | Optimized mini-dystrophin genes and expression cassettes and their use | |
HK1248755A1 (zh) | 主要造血細胞中的蛋白質傳遞 | |
EA201992358A1 (ru) | Тканеселективная экспрессия трансгена | |
MX2023001834A (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. | |
MX2021010668A (es) | Proteinas de fusion de citoquinas. | |
WO2016012544A3 (en) | Enhanced reprogramming to ips cells | |
MX2017002900A (es) | Terapia genica de globina para el tratamiento de hemoglobinopatias. | |
MY181994A (en) | Immuno-modulatory progenitor (imp) cell | |
MX356809B (es) | Animales no humanos que tienen un gen del factor activador de celulas b. | |
MX2021005373A (es) | Variantes de proteinas de union al factor h y metodos de uso de estas. | |
AU2015279552A8 (en) | Neural cells expressing adenovirus E4ORF1, and methods of making and using the same | |
PH12016501689B1 (en) | Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof | |
IL263370A (en) | Improved RNA encoding vegf-a polypeptides, related compositions and uses | |
PH12017500695A1 (en) | Herbicide tolerance genes and methods of use thereof | |
MX2020002903A (es) | Método para potenciar la expresión de arn en una célula. | |
PH12016501447A1 (en) | Zea mays regulatory elements and uses thereof | |
WO2014150748A3 (en) | Stabilized single human cd4 domains and fusion proteins | |
EP2963117A4 (en) | PROTEIN ASSOCIATED WITH A PLANT TYPE, AND GENE ENCODING THE SAME, AND ITS APPLICATION. | |
DK3303215T3 (da) | Palladium-platin-system til brug som hydrogenlagringsmateriale og/eller elektrokatalysator, fortrinsvis i brændselsceller | |
UY36013A (es) | Expresión raíz específica conferida por elementos regulatorios génicos quiméricos, cassette de expresión, vector, plantas y células transgénicas, polinucleotidos y métodos?. | |
GEU20171919Y (en) | Gel for electrotherapy |